Application of the Milan System for Reporting Salivary Gland Cytopathology: A Study of Cytohistological Correlation and Risk of Malignancy
DOI:
https://doi.org/10.21276/apalm.3928Keywords:
salivary gland neoplasm, biopsy, fine-needle, sensitivity and specificity, predictive value of tests, diagnostic errorsAbstract
Background: The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) was introduced in 2018 to provide a uniform, evidence-based framework for reporting salivary gland FNAC, with each diagnostic category linked to an estimated Risk of Malignancy (ROM) and management.
Methods: For each FNAC of salivary gland lesions, whether received in-house or ultrasound-guided, a comprehensive clinical examination of the patient was performed. Descriptive statistical mean and frequency (%) is used to depict the baseline characteristics of demographic data of the study participants. ROM were calculated in each MSRSGC categories and performance analysis with Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Diagnostic accuracy.
Result: This study evaluated 104 salivary gland FNAC cases using the MSRSGC and correlated cytological findings with histopathology wherever available. Benign neoplasms constituted the largest diagnostic category, followed by malignant and non-neoplastic lesions. A male predominance was observed (69.2%), with a peak incidence in the 61–70-year age group. Radiology–cytology concordance was noted in 82.5% of evaluated cases. Histopathological correlation was available in 44 of 104 FNAC cases, as only these patients underwent subsequent surgical excision/biopsy at our institution. The risk of malignancy was calculated for each MSRSGC Categories
Conclusion: Overall, MSRSGC is a simple, user-friendly, and reliable reporting system that enhances communication between pathologists and clinicians and aids in appropriate patient management.
References
1. Jain R, Gupta R, Kudesia M, Singh S. Fine needle aspiration cytology in diagnosis of salivary gland lesions: A study with histologic comparison. CytoJournal. 2013;10:5.
2. Speight PM, Barrett AW. Salivary gland tumours: diagnostic challenges and an update on the latest WHO classification. Diagn Histopathol. 2020;26(4):147–58.
3. Rossi ED, Baloch Z, Barkan G, Foschini MP, Kurtycz D, Pusztaszeri M, et al. The Milan System for Reporting Salivary Gland Cytopathology, 2nd edition. Cancer Cytopathol. 2024;132(1):10–21.
4. Jha S, et al. The Milan System for Reporting Salivary Gland Cytopathology: cytohistological concordance and risk of malignancy. Diagn Cytopathol. 2021;49(1):17–29.
5. Baloch ZW, Faquin WC, Layfield LJ. Is it time to develop a tiered classification scheme for salivary gland fine-needle aspiration specimens? Diagnostic Cytopathology. 2017;45(4).
6. Bajwa MS, Mitchell DA, Brennan PA. Is it time we adopted a classification for parotid gland cytology? The British Journal of Oral & Maxillofacial Surgery. 2014;52(2).
7. Liu CC, Jethwa AR, Khariwala SS, Johnson J, Shin JJ. Sensitivity, specificity, and posttest probability of parotid fine-needle aspiration: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2016;154:9–23. doi: 10.1177/0194599815607841.
8. Zapanta PE, Truelson JM. Salivary Glands, Fine-Needle Aspiration. 2009 Feb;13.
9. Kala C, Kala S, Khan L. Milan system for reporting salivary gland cytopathology: An experience with the implication for risk of malignancy. J Cytol. 2019;36(3):160-4.
10. Amita K, Rakshitha HB, Singh A, Shankar SV. Evaluation of accuracy of Milan system for reporting salivary gland cytology: review of morphology and diagnostic challenges in each category. Journal of Cytology. 2020 Jan 1;37(1):18-25.
11. Rohilla M, Singh P, Rajwanshi A, Gupta N, Srinivasan R, Dey P, Vashishta RK. Three-year cytohistological correlation of salivary gland FNA cytology at a tertiary center with the application of the Milan system for risk stratification. Cancer Cytopathology. 2017 Oct;125(10):767-75.
12. Datta B, Daimary M, Bordoloi K, Thakuria C. Cytopathological spectrum of salivary gland lesions according to Milan reporting system: a retrospective study. Asian Pac J Cancer Care. 2023;8(3):465-70.
13. Maleki Z, Baloch Z, Lu R, Shafique K, Song SJ, Viswanathan K, Rao RA, Lefler H, Fatima A, Wiles A, Jo VY. Application of the Milan system for reporting submandibular gland cytopathology: an international, multi-institutional study. Cancer Cytopathology. 2019 May;127(5):306-15.
14. Das P, Sahoo N, Mohanty P, Batalia P, Pal A. The Milan system for reporting salivary gland cytopathology and cyto-histological correlation with special emphasis on cystic lesions—4 years study in a tertiary care institute. ecancermedicalscience. 2025 Mar 11;19:1870.
15. Vijayakumar G, Narayanan AV, Srikiran TK, Aravind S, Vijay PS. Importance of radio-histo-cytopathological correlation, A retrospective study of cyto-histological and radiological correlation of salivary gland lesions using Milan System for Reporting Salivary Gland Cytopathology. Journal of Cancer Research and Therapeutics. 2024 Jul 1;20(5):1394-9.
16. Huang YT, Ho CY, Ou CY, Huang CC, Lee WT, Tsai SW, Hsu HJ, Hung DS, Tsai CS, Fang SY, Tsai ST. Evaluation of fine needle aspiration cytopathology in salivary gland tumors under Milan system: challenges, misdiagnosis rates, and clinical recommendations. Biomedicines. 2023 Jul 12;11(7):1973.
17. Gomez M, Yu W, Sneige N. The Milan system for reporting salivary gland cytopathology: The experience of a tertiary cancer center with emphasis on non-mucinous cysts and improving diagnostic results. Journal of the American Society of Cytopathology. 2024 Jan 1;13(1):59-66.
18. Reerds ST, van Engen-van Grunsven AC, van den Hoogen FJ, Takes RP, Marres HA, Honings J. Validation of the Milan System for Reporting Salivary Gland Cytopathology and the diagnostic accuracy of FNA cytology for submandibular gland lesions. Cancer Cytopathology. 2022 Mar;130(3):189-94.
19. Pandey N, DasNayak G, Dash K, Senapati U, Rout K. Application of the Milan System of reporting salivary gland cytopathology and assessing its use as a risk stratification tool. Journal of Cancer Research and Therapeutics. 2024 Jul 1;20(5):1517-23.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Hemali Bharatkumar Patel, Hetal Jigar Joshi, Khevna Kansara
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
How to Cite
